Cargando…
The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups
OBJECTIVES: To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk. METHODS: A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Associat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558181/ https://www.ncbi.nlm.nih.gov/pubmed/34019220 http://dx.doi.org/10.1007/s10198-021-01314-z |
_version_ | 1784592498797051904 |
---|---|
author | Lorenzoni, V. Barbieri, G. Saia, F. Meucci, F. Martinelli, G. L. Cerillo, A. G. Berti, S. Candolfi, P. Turchetti, G. |
author_facet | Lorenzoni, V. Barbieri, G. Saia, F. Meucci, F. Martinelli, G. L. Cerillo, A. G. Berti, S. Candolfi, P. Turchetti, G. |
author_sort | Lorenzoni, V. |
collection | PubMed |
description | OBJECTIVES: To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk. METHODS: A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I–IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) were estimated from national tariffs. A scenario analysis considering a micro-costing approach to estimate procedural costs was also considered. The incremental cost-effectiveness ratio (ICER) was expressed both in terms of costs per life years gained (LYG) and costs per quality adjusted life years (QALY). All outcomes and costs were discounted at 3% per annum. Univariate and probabilistic sensitivity analyses (PSA) were performed to assess robustness of results. RESULTS: Over a 15-year time horizon, the higher acquisition costs for TAVI were partially offset in all risk groups because of its effectiveness and safety profile. ICERs were €8338/QALY, €11,209/QALY and €10,133/QALY, respectively, for intermediate-, high-risk and inoperable patients. ICER values were slightly higher in the scenario analysis. PSA suggested consistency of results. CONCLUSIONS: TAVI would be considered cost-effective at frequently cited willingness-to-pay thresholds; further studies could clarify the CE of TAVI in real-life scenarios. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-021-01314-z. |
format | Online Article Text |
id | pubmed-8558181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85581812021-11-15 The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups Lorenzoni, V. Barbieri, G. Saia, F. Meucci, F. Martinelli, G. L. Cerillo, A. G. Berti, S. Candolfi, P. Turchetti, G. Eur J Health Econ Original Paper OBJECTIVES: To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk. METHODS: A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I–IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) were estimated from national tariffs. A scenario analysis considering a micro-costing approach to estimate procedural costs was also considered. The incremental cost-effectiveness ratio (ICER) was expressed both in terms of costs per life years gained (LYG) and costs per quality adjusted life years (QALY). All outcomes and costs were discounted at 3% per annum. Univariate and probabilistic sensitivity analyses (PSA) were performed to assess robustness of results. RESULTS: Over a 15-year time horizon, the higher acquisition costs for TAVI were partially offset in all risk groups because of its effectiveness and safety profile. ICERs were €8338/QALY, €11,209/QALY and €10,133/QALY, respectively, for intermediate-, high-risk and inoperable patients. ICER values were slightly higher in the scenario analysis. PSA suggested consistency of results. CONCLUSIONS: TAVI would be considered cost-effective at frequently cited willingness-to-pay thresholds; further studies could clarify the CE of TAVI in real-life scenarios. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-021-01314-z. Springer Berlin Heidelberg 2021-05-21 2021 /pmc/articles/PMC8558181/ /pubmed/34019220 http://dx.doi.org/10.1007/s10198-021-01314-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Lorenzoni, V. Barbieri, G. Saia, F. Meucci, F. Martinelli, G. L. Cerillo, A. G. Berti, S. Candolfi, P. Turchetti, G. The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups |
title | The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups |
title_full | The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups |
title_fullStr | The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups |
title_full_unstemmed | The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups |
title_short | The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups |
title_sort | cost-effectiveness of transcatheter aortic valve implantation: exploring the italian national health system perspective and different patient risk groups |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558181/ https://www.ncbi.nlm.nih.gov/pubmed/34019220 http://dx.doi.org/10.1007/s10198-021-01314-z |
work_keys_str_mv | AT lorenzoniv thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT barbierig thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT saiaf thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT meuccif thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT martinelligl thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT cerilloag thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT bertis thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT candolfip thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT turchettig thecosteffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT lorenzoniv costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT barbierig costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT saiaf costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT meuccif costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT martinelligl costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT cerilloag costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT bertis costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT candolfip costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups AT turchettig costeffectivenessoftranscatheteraorticvalveimplantationexploringtheitaliannationalhealthsystemperspectiveanddifferentpatientriskgroups |